[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100428320":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":49,"centralContacts":54,"locations":64,"responsibleParty":82,"collaborators":22,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":22,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":22,"maxAge":22,"enrollmentInfo":92,"targetDuration":22,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":22,"overallStatus":66,"whyStopped":22,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Jonsson Comprehensive Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic (99mTc-PSMA-I&S, SPECT\u002FCT)","EXPERIMENTAL","The first 5 patients receive an initial dose of undergo 99mTc-PSMA-I\\&S IV followed by 5 SPECT\u002FCT scans at 3-5, 5-20, 17-21, 25-29, and 40-46 hours later. These 5 patients then receive a second dose of 99mTc-PSMA-I\\&S IV and then undergo standard of care surgery. All subsequent patients receive one dose of 99mTc-PSMA-I\\&S IV before standard of care surgery.",[13,14,15],"Drug: 99mTc-based PSMA Imaging and Surgery Agent","Procedure: Computed Tomography","Procedure: Single Photon Emission Computed Tomography",[17,23,36],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","99mTc-based PSMA Imaging and Surgery Agent","Given via IV injection",[9],null,{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"PROCEDURE","Computed Tomography","Undergo SPECT\u002FCT",[9],[29,30,31,32,33,34,35],"CAT","CAT Scan","Computerized Axial Tomography","Computerized Tomography","CT","CT Scan","tomography",{"type":24,"name":37,"description":26,"armGroupLabels":38,"otherNames":39},"Single Photon Emission Computed Tomography",[9],[40,41,42,43,44,45,46,47,48],"Medical Imaging, Single Photon Emission Computed Tomography","Single Photon Emission Tomography","single-photon emission computed tomography","SPECT","SPECT imaging","SPECT SCAN","SPET","tomography, emission computed, single photon","Tomography, Emission-Computed, Single-Photon",[50],{"name":51,"affiliation":52,"role":53},"Jeremie Calais, MD","UCLA \u002F Jonsson Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[55,60],{"name":56,"role":57,"phone":58,"phoneExt":22,"email":59},"Deepu Varughese","CONTACT","310-206-7372","DVarughese@mednet.ucla.edu",{"name":61,"role":57,"phone":62,"phoneExt":22,"email":63},"Ankush Sachdeva","310-794-3421","ASachdeva@mednet.ucla.edu",[65],{"facility":52,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"RECRUITING","Los Angeles","California","90095","United States","US",{"type":73,"coordinates":74},"Point",[75,76],-118.24368,34.05223,{"lat":76,"lon":75},[79,80,81],{"name":56,"role":57,"phone":58,"phoneExt":22,"email":59},{"name":61,"role":57,"phone":62,"phoneExt":22,"email":63},{"name":51,"role":53,"phone":22,"phoneExt":22,"email":22},{"type":83,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100428320","early-phase-1-99mtc-psma-is-biodistribution-in-patients-with-prostate-cancer-100428320",false,"NCT04857502","99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer","99mTc-PSMA-I&Amp;S in Patients With Prostate Cancer: An Exploratory Biodistribution Study With Histopathology Validation","Inclusion Criteria:\n\n* Men with PCa (primary or recurrent disease)\n* Men who received a 68Ga-PSMA-11 positron emission tomography (PET)\u002Fcomputed tomography (CT) for staging or restaging\n* Men with evidence of lymph nodes (LNs)-positive disease on 68Ga-PSMA-11 PET\u002FCT\n* Men who are scheduled for pelvic LN dissection (PLND)\n* Men who can provide oral and written informed consent\n* Men who can comply with study procedures\n\nExclusion Criteria:\n\n* Patients who started any PCa treatment between study enrollment and surgery\n* Technically inaccessible nodal location","MALE",{"count":93,"type":94},30,"ESTIMATED","INTERVENTIONAL",[97],"EARLY_PHASE1","This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I\\&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I\\&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I\\&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.",[100,101],"Prostate Carcinoma","Recurrent Prostate Carcinoma","2026-03-11",{"date":104,"type":105},"2026-03-13","ACTUAL",{"date":107,"type":105},"2021-04-27",{"date":109,"type":94},"2027-06-01",{"name":5,"class":6},1]